BOSTON , Aug. 5, 2024 /PRNewswire/ -- Antennova, a clinical-stage biotech company focused on oncology today announced that the orally administered CD73 small molecule inhibitor ATN-037 ( also known as ATG-037) has been accepted for Mini Oral presentation at the 2024 European Society of Medical Oncology Congress (EMSO Congress 2024), taking place from September 13 th to September 17 th at the Fira Barcelona Gran Via in Barcelona, Spain . Details of the Presentation: ATN-037 (CD73 Oral Small Molecule Inhibitor) Title: A First-In-Human Phase I/Ib study of ATG-037 Monotherapy and Combination Therapy with Pembrolizumab in Patients with Advanced Solid Tumours – STAMINA-01 Abstract: 6067 Presentation Number: 997MO Date: September 16, 2024 Lecture Time: 10:50 AM – 10:55 AM (Central European Summer Time) 4:50 AM – 4:55 AM (US Eastern Time) About Antennova Antennova, a Delaware corporation and a subsidiary of Antengene (HKEX: 6996), is a clinical-stage biotech company specialized in developing innovative therapeutics that target the critical biological mechanisms that enable cancers to evade and resist treatment by current drugs.
Antennova is developing a pipeline of oncology candidates that can potentially enhance the effectiveness of standard therapies, reverse checkpoint inhibitor (CPI) resistance, and target "cold tumors" that are not responsive to the current CPI therapies. Antennova has achieved significant milestones which include advancing and developing 4 clinical stage .